Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amiodarone
Drug ID BADD_D00115
Description Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings.[A36817] Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
Indications and Usage Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.
Marketing Status Prescription; Discontinued
ATC Code C01BD01
DrugBank ID DB01118
KEGG ID D02910
MeSH ID D000638
PubChem ID 2157
TTD Drug ID D0L5WM
NDC Product Code Not Available
Synonyms Amiodarone | Amiodarona | Amiodarone Hydrochloride | Hydrochloride, Amiodarone | Amiohexal | Aratac | Tachydaron | Corbionax | Cordarone | Amiodarex | Trangorex | Kordaron | Cordarex | L-3428 | L 3428 | L3428 | Ortacrone | Rytmarone | SKF 33134-A | SKF 33134 A | SKF 33134A | Amiobeta | Braxan
Chemical Information
Molecular Formula C25H29I2NO3
CAS Registry Number 1951-25-3
SMILES CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Corneal opacity06.06.03.0050.000893%Not Available
Cough22.02.03.0010.054763%
Crepitations08.01.03.0060.000595%Not Available
Cyanosis02.01.02.002; 22.02.02.007; 24.03.01.0070.000893%
Death08.04.01.001--
Dehydration14.05.05.001--
Delirium19.13.02.001--
Deposit eye06.09.04.0050.000621%Not Available
Depression19.15.01.0010.012500%
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.0020.000595%
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diabetes mellitus inadequate control05.06.01.004; 14.06.01.0040.000595%Not Available
Diaphragmatic paralysis17.01.04.014; 22.09.02.0020.001191%Not Available
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.000893%Not Available
Diplopia06.02.06.002; 17.17.01.0050.000893%Not Available
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Disturbance in attention17.03.03.001; 19.21.02.0020.006845%
Diverticulitis07.10.02.001; 11.01.07.0030.000595%Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.0070.033929%
Drug abuse19.07.02.010--Not Available
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.001--Not Available
Drug hypersensitivity10.01.01.0010.026786%Not Available
Drug interaction08.06.03.001--Not Available
Dry eye06.08.02.0010.001191%
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyskinesia17.01.02.0060.000893%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene